Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global burden of oesophageal and gastric cancer by histology and subsite in 2018
Melina Arnold, Jacques Ferlay, Mark I. van Berge Henegouwen, et al.
Gut (2020) Vol. 69, Iss. 9, pp. 1564-1571
Open Access | Times Cited: 433

Showing 26-50 of 433 citing articles:

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial
Ken Kato, Yuichiro� Doki, Ian Chau, et al.
Cancer Medicine (2024) Vol. 13, Iss. 9
Open Access | Times Cited: 14
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
Jens Hoeppner, Thomas Brunner, Claudia Schmoor, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 4, pp. 323-335
Closed Access | Times Cited: 5
Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2021
Manon C.W. Spaander, Ruben D. van der Bogt, Todd H. Baron, et al.
Endoscopy (2021) Vol. 53, Iss. 07, pp. 751-762
Open Access | Times Cited: 100
Global and regional estimates of orphans attributed to maternal cancer mortality in 2020
Florence Guida, Rachel Kidman, Jacques Ferlay, et al.
Nature Medicine (2022) Vol. 28, Iss. 12, pp. 2563-2572
Open Access | Times Cited: 66
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
Dobrina Tsvetkova, Stefka Ivanova
Molecules (2022) Vol. 27, Iss. 8, pp. 2466-2466
Open Access | Times Cited: 62
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
Ralf‐Dieter Hofheinz, Kirsten Merx, Georg Martin Haag, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 32, pp. 3750-3761
Closed Access | Times Cited: 58
Squamous Cell Carcinoma of the Esophagus
Don C. Codipilly, Kenneth K. Wang
Gastroenterology Clinics of North America (2022) Vol. 51, Iss. 3, pp. 457-484
Closed Access | Times Cited: 48
Global and national trends in the age‐specific sex ratio of esophageal cancer and gastric cancer by subtype
Shaoming Wang, Rongshou Zheng, Melina Arnold, et al.
International Journal of Cancer (2022) Vol. 151, Iss. 9, pp. 1447-1461
Open Access | Times Cited: 47
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
Tianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
International Journal of Cancer (2022) Vol. 152, Iss. 4, pp. 749-760
Open Access | Times Cited: 47
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis
Tarang Sharma, Ashna Gupta, Ravi Chauhan, et al.
Cancer and Metastasis Reviews (2022) Vol. 41, Iss. 2, pp. 281-299
Open Access | Times Cited: 43
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)
Ken Kato, Yuichiro� Doki, Takashi Ogata, et al.
Esophagus (2022) Vol. 20, Iss. 2, pp. 291-301
Open Access | Times Cited: 39
Gastric Cancer Epidemiology: Current Trend and Future Direction
Chidozie Declan Iwu, Chinwe Juliana Iwu
Hygiene (2023) Vol. 3, Iss. 3, pp. 256-268
Open Access | Times Cited: 38
Improving outcomes in patients with oesophageal cancer
Manish A. Shah, Nasser K. Altorki, Pretish Patel, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 6, pp. 390-407
Closed Access | Times Cited: 37
Longitudinal body mass index and cancer risk: a cohort study of 2.6 million Catalan adults
Martina Recalde, Andrea Pistillo, Verónica Dávila‐Batista, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 31
Epidemiological landscape of esophageal cancer in Asia: Results from GLOBOCAN 2020
Hongcheng Zhu, Zezhou Wang, Bingbin Deng, et al.
Thoracic Cancer (2023) Vol. 14, Iss. 11, pp. 992-1003
Open Access | Times Cited: 29
Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study
Ye Gao, Lei Xin, Lin Han, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 5, pp. 432-445
Closed Access | Times Cited: 26
Stomach cancer burden in China: Epidemiology and prevention
Xinxin Yan, Lin Lei, He Li, et al.
Chinese Journal of Cancer Research (2023) Vol. 35, Iss. 2, pp. 81-91
Open Access | Times Cited: 26
Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
Lulu Liu, Lei Wang, Li Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
Baihua Zhang, Hongbo Zhao, Xun Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Long-Term Exposure to Fine Particulate Matter and Incidence of Esophageal Cancer: A Prospective Study of 0.5 Million Chinese Adults
Dong Sun, Cong Liu, Yunqing Zhu, et al.
Gastroenterology (2023) Vol. 165, Iss. 1, pp. 61-70.e5
Open Access | Times Cited: 22
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
Jin Li, Zhendong Chen, Yuxian Bai, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 740-748
Open Access | Times Cited: 14
Burdens of stomach and esophageal cancer from 1990 to 2019 and projection to 2030 in China: Findings from the 2019 Global Burden of Disease Study
Qianwei Jiang, Yiyang Shu, Zhongyi Jiang, et al.
Journal of Global Health (2024) Vol. 14
Open Access | Times Cited: 13
Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000–19: a retrospective, cross-sectional, population-based study
Shilpa S. Murthy, Dario Trapani, Bochen Cao, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. 969-978
Open Access | Times Cited: 12
Burden of Stomach Cancer Incidence, Mortality, Disability-Adjusted Life Years, and Risk Factors in 204 Countries, 1990–2019: An Examination of Global Burden of Disease 2019
Rajesh Sharma
Journal of Gastrointestinal Cancer (2024) Vol. 55, Iss. 2, pp. 787-799
Closed Access | Times Cited: 11
Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial
Ning Jiang, Jingyuan Zhang, Zhen Guo, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e008229-e008229
Open Access | Times Cited: 10

Scroll to top